Developer docs
API playgroundTry for free, no card

Search company profiles

CellVoyant Technologies

Full company profile

uuid00021rp

Namestring
CellVoyant Technologies
Legal namestring
CellVoyant Technologies Limited
Websiteurl
cellvoyant.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

CellVoyant Technologies Limited is a Bristol, UK-based AI biotechnology company spun out of the University of Bristol that develops a Cell Predictive AI Platform for cell-based therapeutic developers and biopharmaceutical manufacturers. The company's core product proposition is replacing slow, endpoint-assay-driven cell culture workflows with predictive, label-free live-cell imaging analytics, targeting pain points around late failure detection, high batch variability, and costly trial-and-error iteration in stem cell and cell therapy development pipelines.

The platform is delivered through two integrated products. FateView™ is a cloud-based, secure SaaS platform where users upload label-free microscopy images (brightfield or phase-contrast) and receive AI-generated predictions of current and future cell states, critical quality attributes, and likely experimental outcomes; features include cell detection, colony detection, pluripotency assessment, and differentiation tracking, accessed via browser or API. FateDrive™ is an AI-driven process optimization service that models, simulates, and prioritizes process conditions in silico, and integrates with FateView™ for closed-loop optimization when connected to automation systems such as Automata's LINQ™ platform. The underlying technology combines proprietary computer vision and machine learning models trained on large-scale time-series imaging datasets, with reported performance gains of up to 8× higher yield, 60% fewer failed experiments, and 40% less waste in partner workflows.

CellVoyant operates a hybrid go-to-market combining product-led growth (30-day free trial of FateView™ with no credit card required, followed by quote-based subscription) and enterprise field sales targeting biotech and pharmaceutical companies developing cell-based therapies. Revenue streams comprise SaaS subscriptions on FateView™, subscription-based FateDrive™ optimization engagements, and professional services for custom assay development. The company is venture-backed (a £7.6M seed round led by Octopus Ventures in January 2024, with Air Street Capital, Horizons Ventures, Compound, and Verve Ventures participating), has a team of ~14 scientists and engineers, and is pursuing strategic partnerships across the iPSC supply chain (Pluristyx, Axol Bioscience) and laboratory automation (Automata) to embed its platform in customer bioprocess workflows.

Short descriptiontext

CellVoyant Technologies is an AI-native biotech company building a Cell Predictive AI Platform (FateView™ and FateDrive™) that applies computer vision and machine learning to label-free live-cell imaging for cell therapy developers and biopharmaceutical manufacturers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBristol, United Kingdom
HQ citystring
Bristol
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
predictive cell analytics, label-free imaging, cell process optimization, stem cell bioprocessing, AI drug discovery
Industry4 codes
PRIMARYHDAAAHAL
Scenario Planning, Forecasting Platforms & Planning Intelligence
SECONDARYHDAAACAB
Model Hosting, Serving & Inference Platforms
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
SECONDARYHDAAABAF
Model Deployment, Serving & Inference Platforms
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/ML Platforms, MLOps & Model Lifecycle Management
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Computer Systems Design Services541512
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
AI Cell Analytics Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1FateView™ SaaS Platform
TypeSubscription Recurring
Description

Cloud-based subscription platform offering predictive cell analytics. Users access via secure browser interface or API with tiered pricing based on usage. Free trial available for initial onboarding, followed by paid subscription.

cellvoyant.com
2FateDrive™ Optimization Services
TypeSubscription Recurring
Description

AI-driven process optimization service working alongside customer teams on science-led optimization. Combines predictive inputs from FateView with in-silico modeling to guide experimental and manufacturing decisions.

cellvoyant.com
3Custom Assay Development
TypeProfessional Services
Description

Tailored assay development for specific phenotypes of interest and custom readouts. Professional service engagement for organizations with specialized process requirements.

cellvoyant.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Free Trial - 30-day access to core features
ModelFreemiumBilling cadencePay-as-you-go
Notes

30-day free trial with allocated trial credits for exploring core features. No credit card required.

cellvoyant.com
2Paid Subscription - Full platform access
ModelSubscriptionBilling cadenceAnnual
Notes

Full platform access with extended capabilities, API access, and priority support. Quote-based pricing.

cellvoyant.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1FateView™
Description

AI-powered predictive cell analytics platform for label-free live-cell image analysis to infer cell state and likely outcomes

cellvoyant.com
+1 more record
Core offering1 text field

CellVoyant sells an AI Cell Predictive Platform comprising two products: FateView™, a cloud-based SaaS that applies computer vision and machine learning to label-free live-cell microscopy images to predict cell state, critical quality attributes (CQAs), and likely outcomes; and FateDrive™, an AI-driven process optimization service that models and simulates cell culture conditions to guide experimental and manufacturing decisions and integrates with FateView for closed-loop workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 60% fewer failed experiments by identifying differentiation failure before typical assays detect issues
+4 more records
Product overview1 text field

CellVoyant operates as an AI-First company offering a Cell Predictive AI Platform consisting of two integrated core products: FateView™ and FateDrive™. FateView™ is a cloud-based platform providing label-free AI image analysis to predict cell state and outcomes from live-cell microscopy images. FateDrive™ is an AI-driven optimisation service that models and simulates process conditions to guide decisions. Together, they enable adaptive process control by combining real-time measurement with model-driven optimisation, supporting closed-loop workflows when integrated with automation systems like Automata LINQ™.

Product and service3 records
1FateView™
CategoryAI Cell Analytics Platform
Description

Cloud-based, label-free AI image analysis SaaS platform that ingests live-cell transmitted-light microscopy images and returns predictions of current and future cell states, critical quality attributes (CQAs), and likely experimental outcomes. Targeted at biotech and pharmaceutical R&D teams developing cell-based therapeutics, including stem cell, iPSC-derived, and CAR-T programs.

2FateDrive™
CategoryAI Process Optimization Service
Description

AI-driven process optimization service that models, simulates, and prioritizes cell culture process conditions to guide experimental and manufacturing decisions. Works alongside customer teams to deliver science-led optimization and integrates with FateView for real-time, closed-loop bioprocess optimization. Targeted at bioprocess development and manufacturing teams in cell therapy and biologics organizations.

3Custom Assay Development
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Strategic collaboration to develop AI-guided predictive imaging assays for cardiomyocyte manufacturing. Integration of FateView platform with Axol Bioscience's iPSC differentiation and heart chamber-specific cardiomyocyte production expertise. Focus on non-invasive, label-free methods for predicting and guiding differentiation processes to generate highly pure cell populations at scale.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-07
Description

Strategic partnership combining CellVoyant's predictive AI platform with Pluristyx's human iPSC technologies to co-develop AI-characterised iPSC products. Joint initiative to integrate continuous, non-destructive insights onto traditional manufacturing workflows, moving toward more data-rich, predictive assessments of cell behavior for enhanced cell therapy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-23
Description

Strategic partnership integrating FateDrive with Automata's LINQ lab automation platform to enable AI-powered, closed-loop cell culture optimisation. The collaboration brings together predictive analytics, in-silico optimisation, and modular lab automation for autonomous cell culture workflows. Demonstrated 8× improvement in differentiation efficiency in cardiomyocyte differentiation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Culture Biosciences
TypeEmerging player
Description

Biotech offering automated bioreactor and bioprocess development services with cloud-based monitoring. Comparable in bringing digital and AI-driven optimization to bioprocess workflows.

2Tempus AI
TypeBroad incumbent
Description

AI and data platform for life sciences and pharma with broad applications across R&D and clinical workflows. Larger, broader incumbent applying AI to pharma and biotech data at scale.

TypeEmerging player
Description

AI-driven antibody and biologics discovery platform using high-throughput experimentation and ML. Adjacent AI-for-biotech-discovery competitor with overlapping biopharma customer base.

TypeDirect peer
Description

AI company building cell-biology models for biopharma R&D and drug development. Direct comparable in applying AI to predict cellular behavior and disease mechanisms for pharma customers.

TypeBroad incumbent
Description

Major supplier of cell therapy manufacturing and bioprocess solutions to pharma and biotech. Incumbent in the cell therapy manufacturing stack that CellVoyant's FateDrive optimization platform targets.

TypeDirect peer
Description

AI-driven drug discovery company leveraging high-content imaging and foundation models across large-scale cellular datasets. Comparable in pairing AI with image-based cellular phenotyping for therapeutic discovery.

TypeBroad incumbent
Description

AI platform for biopharma R&D combining multimodal data and ML to accelerate drug development. Comparable AI-for-biopharma enterprise go-to-market with pharma customers.

TypeDirect peer
Description

AI-native biotech using machine learning and high-content cellular imaging to model disease and discover therapeutics. Closest comparable in combining AI/computer vision with cell biology at scale for biopharma R&D.

9PhenomeX (formerly Berkeley Lights)
TypeDirect peer
Description

Provider of single-cell analysis and functional cell biology instrumentation used in cell therapy development and bioprocess optimization. Comparable in serving cell therapy developers with imaging-based analytics tools.

TypeBroad incumbent
Description

Large bioprocess solutions provider including cell line development, analytical instruments, and bioprocess automation. Established incumbent with overlapping customers in cell therapy and bioprocess analytics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellVoyant Technologies

AI Cell Analytics Softwarecellvoyant.com

CellVoyant Technologies is an AI-native biotech company building a Cell Predictive AI Platform (FateView™ and FateDrive™) that applies computer vision and machine learning to label-free live-cell imaging for cell therapy developers and biopharmaceutical manufacturers.

What CellVoyant Technologies does

CellVoyant Technologies Limited is a Bristol, UK-based AI biotechnology company spun out of the University of Bristol that develops a Cell Predictive AI Platform for cell-based therapeutic developers and biopharmaceutical manufacturers. The company's core product proposition is replacing slow, endpoint-assay-driven cell culture workflows with predictive, label-free live-cell imaging analytics, targeting pain points around late failure detection, high batch variability, and costly trial-and-error iteration in stem cell and cell therapy development pipelines.

The platform is delivered through two integrated products. FateView™ is a cloud-based, secure SaaS platform where users upload label-free microscopy images (brightfield or phase-contrast) and receive AI-generated predictions of current and future cell states, critical quality attributes, and likely experimental outcomes; features include cell detection, colony detection, pluripotency assessment, and differentiation tracking, accessed via browser or API. FateDrive™ is an AI-driven process optimization service that models, simulates, and prioritizes process conditions in silico, and integrates with FateView™ for closed-loop optimization when connected to automation systems such as Automata's LINQ™ platform. The underlying technology combines proprietary computer vision and machine learning models trained on large-scale time-series imaging datasets, with reported performance gains of up to 8× higher yield, 60% fewer failed experiments, and 40% less waste in partner workflows.

CellVoyant operates a hybrid go-to-market combining product-led growth (30-day free trial of FateView™ with no credit card required, followed by quote-based subscription) and enterprise field sales targeting biotech and pharmaceutical companies developing cell-based therapies. Revenue streams comprise SaaS subscriptions on FateView™, subscription-based FateDrive™ optimization engagements, and professional services for custom assay development. The company is venture-backed (a £7.6M seed round led by Octopus Ventures in January 2024, with Air Street Capital, Horizons Ventures, Compound, and Verve Ventures participating), has a team of ~14 scientists and engineers, and is pursuing strategic partnerships across the iPSC supply chain (Pluristyx, Axol Bioscience) and laboratory automation (Automata) to embed its platform in customer bioprocess workflows.

CellVoyant Technologies firmographics

Firmographics
Name
CellVoyant Technologies
Legal name
CellVoyant Technologies Limited
Website
https://cellvoyant.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
CellVoyant Technologies is an AI-native biotech company building a Cell Predictive AI Platform (FateView™ and FateDrive™) that applies computer vision and machine learning to label-free live-cell imaging for cell therapy developers and biopharmaceutical manufacturers.
Ownership category
akta.pro rank

CellVoyant Technologies industry classification

Industry
Product category
AI Cell Analytics Software
NAICS
Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHDAAAHAL
Scenario Planning, Forecasting Platforms & Planning Intelligence
SECONDARYHDAAACAB
Model Hosting, Serving & Inference Platforms
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
SECONDARYHDAAABAF
Model Deployment, Serving & Inference Platforms
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/ML Platforms, MLOps & Model Lifecycle Management
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Predictive cell analytics
  • Label-free imaging
  • Cell process optimization
  • Stem cell bioprocessing
  • AI drug discovery

Where CellVoyant Technologies is headquartered

Location

Headquarters

HQ city
Bristol
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

CellVoyant Technologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. FateView™ SaaS Platform: Cloud-based subscription platform offering predictive cell analytics. Users access via secure browser interface or API with tiered pricing based on usage. Free trial available for initial onboarding, followed by paid subscription.
  2. FateDrive™ Optimization Services: AI-driven process optimization service working alongside customer teams on science-led optimization. Combines predictive inputs from FateView with in-silico modeling to guide experimental and manufacturing decisions.
  3. Custom Assay Development: Tailored assay development for specific phenotypes of interest and custom readouts. Professional service engagement for organizations with specialized process requirements.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree Trial - 30-day access to core features
SubscriptionAnnualPaid Subscription - Full platform access

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

CellVoyant Technologies product offering

Product offering

Core offering

CellVoyant sells an AI Cell Predictive Platform comprising two products: FateView™, a cloud-based SaaS that applies computer vision and machine learning to label-free live-cell microscopy images to predict cell state, critical quality attributes (CQAs), and likely outcomes; and FateDrive™, an AI-driven process optimization service that models and simulates cell culture conditions to guide experimental and manufacturing decisions and integrates with FateView for closed-loop workflows.

Product overview

CellVoyant operates as an AI-First company offering a Cell Predictive AI Platform consisting of two integrated core products: FateView™ and FateDrive™. FateView™ is a cloud-based platform providing label-free AI image analysis to predict cell state and outcomes from live-cell microscopy images. FateDrive™ is an AI-driven optimisation service that models and simulates process conditions to guide decisions. Together, they enable adaptive process control by combining real-time measurement with model-driven optimisation, supporting closed-loop workflows when integrated with automation systems like Automata LINQ™.

Differentiator

Problem solved

Functional benefit

Brands

  • FateView™: AI-powered predictive cell analytics platform for label-free live-cell image analysis to infer cell state and likely outcomes
  • FateDrive™

Products and services

  • FateView™ Cloud-based, label-free AI image analysis SaaS platform that ingests live-cell transmitted-light microscopy images and returns predictions of current and future cell states, critical quality attributes (CQAs), and likely experimental outcomes. Targeted at biotech and pharmaceutical R&D teams developing cell-based therapeutics, including stem cell, iPSC-derived, and CAR-T programs.
  • FateDrive™ AI-driven process optimization service that models, simulates, and prioritizes cell culture process conditions to guide experimental and manufacturing decisions. Works alongside customer teams to deliver science-led optimization and integrates with FateView for real-time, closed-loop bioprocess optimization. Targeted at bioprocess development and manufacturing teams in cell therapy and biologics organizations.
  • Custom Assay Development

Quantifiable outcome

  • Up to 60% fewer failed experiments by identifying differentiation failure before typical assays detect issues
  • +4 more outcomes

Companies that use CellVoyant Technologies

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

CellVoyant Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature5 records

CellVoyant Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Axol BiosciencecoreStrategic or Co-development Partner · 9 June 2026Strategic collaboration to develop AI-guided predictive imaging assays for cardiomyocyte manufacturing. Integration of FateView platform with Axol Bioscience's iPSC differentiation and heart chamber-specific cardiomyocyte production expertise. Focus on non-invasive, label-free methods for predicting and guiding differentiation processes to generate highly pure cell populations at scale.
  • PluristyxcoreStrategic or Co-development Partner · 7 May 2026Strategic partnership combining CellVoyant's predictive AI platform with Pluristyx's human iPSC technologies to co-develop AI-characterised iPSC products. Joint initiative to integrate continuous, non-destructive insights onto traditional manufacturing workflows, moving toward more data-rich, predictive assessments of cell behavior for enhanced cell therapy development.
  • AutomatacoreStrategic or Co-development Partner · 23 January 2026Strategic partnership integrating FateDrive with Automata's LINQ lab automation platform to enable AI-powered, closed-loop cell culture optimisation. The collaboration brings together predictive analytics, in-silico optimisation, and modular lab automation for autonomous cell culture workflows. Demonstrated 8× improvement in differentiation efficiency in cardiomyocyte differentiation.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

CellVoyant Technologies competitors and assessment

Company assessment

Emerging players

  • Culture Biosciences: Biotech offering automated bioreactor and bioprocess development services with cloud-based monitoring. Comparable in bringing digital and AI-driven optimization to bioprocess workflows.
  • AbCellera Biologics: AI-driven antibody and biologics discovery platform using high-throughput experimentation and ML. Adjacent AI-for-biotech-discovery competitor with overlapping biopharma customer base.

Broad incumbents

  • Tempus AI: AI and data platform for life sciences and pharma with broad applications across R&D and clinical workflows. Larger, broader incumbent applying AI to pharma and biotech data at scale.
  • Cytiva (Danaher): Major supplier of cell therapy manufacturing and bioprocess solutions to pharma and biotech. Incumbent in the cell therapy manufacturing stack that CellVoyant's FateDrive optimization platform targets.
  • Owkin: AI platform for biopharma R&D combining multimodal data and ML to accelerate drug development. Comparable AI-for-biopharma enterprise go-to-market with pharma customers.
  • Sartorius: Large bioprocess solutions provider including cell line development, analytical instruments, and bioprocess automation. Established incumbent with overlapping customers in cell therapy and bioprocess analytics.

Direct peers

  • CytoReason: AI company building cell-biology models for biopharma R&D and drug development. Direct comparable in applying AI to predict cellular behavior and disease mechanisms for pharma customers.
  • Recursion Pharmaceuticals: AI-driven drug discovery company leveraging high-content imaging and foundation models across large-scale cellular datasets. Comparable in pairing AI with image-based cellular phenotyping for therapeutic discovery.
  • Insitro: AI-native biotech using machine learning and high-content cellular imaging to model disease and discover therapeutics. Closest comparable in combining AI/computer vision with cell biology at scale for biopharma R&D.
  • PhenomeX (formerly Berkeley Lights): Provider of single-cell analysis and functional cell biology instrumentation used in cell therapy development and bioprocess optimization. Comparable in serving cell therapy developers with imaging-based analytics tools.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

CellVoyant Technologies social profiles

Digital presence

CellVoyant Technologies compliance and trust

Trust signal

Compliance2 records

CellVoyant Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellVoyant Technologies leadership team

Management profile

Number of profiles

Profiles10 records

CellVoyant Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellVoyant Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellVoyant Technologies

What does CellVoyant Technologies do?

CellVoyant sells an AI Cell Predictive Platform comprising two products: FateView™, a cloud-based SaaS that applies computer vision and machine learning to label-free live-cell microscopy images to predict cell state, critical quality attributes (CQAs), and likely outcomes; and FateDrive™, an AI-driven process optimization service that models and simulates cell culture conditions to guide experimental and manufacturing decisions and integrates with FateView for closed-loop workflows.

Is CellVoyant Technologies a public or private company?

CellVoyant Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellVoyant Technologies founded?

CellVoyant Technologies was founded in 2021. It employs 11 to 50 people.

Where is CellVoyant Technologies based?

CellVoyant Technologies is headquartered in Bristol, United Kingdom, in the Europe region.

How does CellVoyant Technologies make money?

Three revenue lines are on record. FateView™ SaaS Platform is the primary driver. The others are fateDrive™ Optimization Services and custom Assay Development.

Who are CellVoyant Technologies's main competitors?

Emerging players on record are Culture Biosciences and AbCellera Biologics. Broad incumbents are Tempus AI, Cytiva (Danaher), Owkin and Sartorius. Direct peers are CytoReason, Recursion Pharmaceuticals, Insitro and PhenomeX (formerly Berkeley Lights).

Does CellVoyant Technologies have an API?

Yes. FateView™ provides flexible platform access via secure browser interface or API, designed to integrate seamlessly with existing workflows. Predictive analytics and metadata can be exported for use in automation systems, data platforms, or adaptive culture management pipelines. Developer documentation is at fateview.cellvoyant.com.

What industry is CellVoyant Technologies in?

CellVoyant Technologies's product category is AI Cell Analytics Software. Its primary akta.pro industry code is HDAAAHAL, Scenario Planning, Forecasting Platforms & Planning Intelligence, with a secondary code of HDAAACAB, Model Hosting, Serving & Inference Platforms. Its NAICS code is 54151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Built In5 Bristol Biotech Companies to KnowBristol's biotech scene includes Ecolab, Lovehoney Group, Bio-Techne, Zentraxa, and CellVoyant. Ecolab advances water sustainability, Bio-Techne supplies research reagents, and CellVoyant uses AI for stem cell treatments. The UK has thousands of biotech patents, making these companies notable.FortuneCellVoyant debuts AI platform that could slash the cost of CAR-T and other cell-based treatmentsUK-based startup CellVoyant has launched FateView, an AI platform that predicts cell health and future performance from microscope images to reduce waste in cell-based therapy production. The technology aims to significantly lower the high costs associated with treatments like CAR-T immunotherapy by improving selection efficiency and reducing reliance on destructive testing. Early adopter Rinri Therapeutics is utilizing the platform to enhance the cost-effectiveness and scalability of its regenerative hearing loss therapies.News-MedicalCellVoyant's AI-Powered Vision for the Future of Cell TherapyCellVoyant CEO Rafael Carazo Salas explains how AI and live-cell imaging predict cell behavior to accelerate cell therapy development. He highlights that scaling living therapies is difficult due to batch failures and high costs, and that AI can reduce clinical trial risks. He also notes regulatory and manufacturing barriers remain.FinSMEsCellVoyant Raises £7.6M in Seed FundingCellVoyant, a Bristol-based biotechnology spin-out from the University of Bristol, has raised £7.6 million in seed funding led by Octopus Ventures with participation from Horizons Ventures, Verve Ventures, and Air Street Capital. The company plans to utilize the capital to double its workforce over the next two years while expanding laboratory infrastructure and advancing its AI-driven stem cell therapy development capabilities.BusinessCloud£7.6m backing for MedTech pioneering stem cell therapy AICellVoyant, a Bristol-based MedTech spinout, raised a £7.6 million seed round led by Octopus Ventures to commercialize its AI and imaging platforms for stem cell therapies. The company's technology aims to improve cell therapy development, with potential savings of $10-100m per therapy. Proceeds will fund headcount, infrastructure, and R&D.BusinessCloud£7.6m backing for MedTech pioneering stem cell therapy AIBristol-based MedTech spinout CellVoyant has secured a £7.6 million seed funding round led by Octopus Ventures to advance its AI and imaging platforms for stem cell therapy development. The company aims to use its technology to improve the precision, speed, and cost-effectiveness of creating novel cell treatments for chronic diseases such as cancer and diabetes. This investment marks the first stage in commercializing CellVoyant's platform, which is designed to reduce the high failure rates currently associated with cell therapy assets.UKTNBristol’s CellVoyant raises £7.6m to predict stem cell behaviour with AIBristol-based biotech startup CellVoyant has secured £7.6m in seed funding led by Octopus Ventures to commercialise its AI-powered imaging technology for predicting stem cell behaviour. The company plans to use the capital to expand its scientific and engineering teams and laboratory facilities, following a previous pre-seed round in 2021.PharmaTimesCellVoyant secures £7.6 million AI stem cell boostCellVoyant, an AI biotechnology spin-out from the University of Bristol, has secured a £7.6 million funding round led by Octopus Ventures with participation from Horizons Ventures, Air Street Capital, and Verve Ventures. The company aims to use these funds to commercialize its AI and imaging platform for stem cell analysis and accelerate the development of novel cell therapies. This investment validates CellVoyant's approach to combining advanced AI with live cell imaging to forecast cell evolution and enhance R&D capabilities.Business InsiderThe pandemic was a crisis that fueled interest in novel drug discovery methods like AI. These 14 startups are predicted by investors to be future winners.The article profiles 14 startups using AI for drug discovery, including CellVoyant, Coding.bio, and Healx. It highlights their technologies, such as AI-driven cell therapy, quantum computing, and machine learning for genomics. The startups are predicted by investors to be future winners in the field.Business InsiderThe pandemic was a crisis that fueled interest in novel drug discovery methods like AI. These 14 startups are predicted by investors to be future winners.The article profiles 14 AI-driven drug-discovery startups, including CellVoyant, Coding.bio, and Healx, which use machine learning, quantum computing, or natural-product screening. Many have raised significant funding, such as Healx's $71 million and ImCheck's $103 million, and aim to accelerate therapies for cancer, rare diseases, and other conditions.